Status:
COMPLETED
Contingency Management in HIV Care for Both Stimulant Use & ART Adherence
Lead Sponsor:
University of California, San Francisco
Conditions:
Stimulant Use (Diagnosis)
Hiv
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Methamphetamine use and associated sequelae have been rising, and represent a major barrier to successful control of the HIV epidemic. Methamphetamine use is associated with poor adherence to antiretr...
Detailed Description
Methamphetamine (MA) use is increasing in the United States, along with a sharp rise in overdose deaths. MA use is particularly prevalent among people with HIV (PWH), which can contribute to non-adher...
Eligibility Criteria
Inclusion
- Stimulant use disorder
- Living with HIV or risk for HIV
- Suboptimal ART adherence (treatment or prevention)
Exclusion
- Unable to provide urine testing weekly
Key Trial Info
Start Date :
September 15 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2025
Estimated Enrollment :
37 Patients enrolled
Trial Details
Trial ID
NCT06564792
Start Date
September 15 2023
End Date
October 1 2025
Last Update
October 14 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UCSF at San Francisco General Hospital
San Francisco, California, United States, 94110